Novartis unit Sandoz agrees to pay $195 million to resolve antitrust charges

Novartis' generic drugs unit Sandoz has agreed to pay $195 million to reach a deferred prosecution agreement aimed at resolving antitrust charges, the Justice Department said on Monday.